An interventional study of Exablate MR-guided Focused Ultrasound Pallidotomy and Sham Sham Exablate MRgFUS Pallidotomy in Limb Dystonia, Idiopathic Dystonia and Medication-refractory Dystonia, sponsored by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta. Recruiting at 4 sites in Italy. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Dystonia with a site in Italy — 5 open to participants now, 6 under way, none of them phase 3. Dystonia · Italy.
Among the 11 studies in Dystonia with a site in Italy, this one is the only one that started in 2025, is one of 2 with no phase, and was the 11th registered.
213 studies on the registry are indexed under Dystonia; 54 are open to participants now.
Browse Dystonia studies →5 of the 11 studies in Dystonia with a site in Italy are open now. Recruiting first, the newest first:
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · Sites in Italy
Ages 12+
Abbott Medical Devices · Sites in Italy, United States, Australia and 6 more countries
Boston Scientific Corporation · Sites in Italy, United States, Belgium and 3 more countries
Boston Scientific Corporation · Sites in Italy, Belgium, Canada and 9 more countries
Ages 7+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 41 Dystonia studies recruiting now, 19 (46%) set no upper age limit and 10 (24%) stop at 75 or younger; 18 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2025.
This study's planned enrollment of 34 is above the median of 28 across 114 interventional studies indexed under Dystonia.
Median enrollment 86 across the 3 interventional studies, 703 across the 8 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 11 have an industry lead sponsor. The 8 most frequent:
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta is the lead sponsor of 84 studies on the registry; 32 are open to participants now.
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta has 2 studies filed under Dystonia — fewer than ten, so there is no comparison to draw.
1 of the studies in Dystonia with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07168850Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaFocused Ultrasound Unilateral Pallidotomy for Medication-Refractory Limb Dystonia | 2027-02-28 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Dystonia with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to find out if a non-invasive procedure called focused ultrasound can safely and effectively treat limb dystonia in adults who have not improved with medications or botulinum toxin injections.
The main questions it aims to answer are:
Researchers will compare people who receive focused ultrasound treatment to those who receive a sham procedure (a look-alike procedure without active treatment) to see if the treatment works.
Focused ultrasound works by producing a very small (millimeter-size) lesion in a deep brain region. In this study, the lesion is located in a region called globus pallidus, which helps control movement.
Participants will:
This study may offer a new non-surgical treatment option for people with dystonia affecting the arm or leg, whose pharmacological control is unsatisfactory.
The FUTURE study is a prospective, randomized, double-blind, sham-controlled, multicenter national clinical trial aimed at assessing the efficacy and safety of unilateral MR-guided focused ultrasound (MRgFUS) pallidotomy in patients with limb dystonia that is refractory to standard pharmacological treatments.
Dystonia is a movement disorder characterized by sustained or intermittent muscle contractions, causing abnormal movements or postures. In many cases, focal or segmental dystonias affecting the limbs can be managed with oral medications and botulinum toxin (BoNT) injections. However, a subset of patients does not respond adequately to these treatments. For such individuals, surgical intervention may offer relief, yet it remains underutilized due to concerns about invasiveness and complications.
Recent advancements in non-invasive neurosurgical techniques have introduced MRgFUS pallidotomy, a procedure that uses focused ultrasound beams under real-time MRI guidance to precisely ablate small brain targets-in this case, the globus pallidus internus (GPi). The FUTURE study specifically explores this technique as a less invasive alternative to deep brain stimulation, especially for patients with focal or segmental limb dystonia who are ineligible or reluctant to undergo conventional surgery.
The trial will enroll 34 adult patients with idiopathic or genetic limb dystonia that has proven resistant to pharmacologic and BoNT treatment. These patients will be randomly assigned in a 1:1 ratio to either:
At three months post-randomization, all patients in the sham group will cross over to receive the active MRgFUS treatment, allowing within-subject comparisons while ensuring ethical access to the therapeutic intervention. The follow-up period for each patient will last six months after active treatment, totaling a maximum of nine months of participation.
The primary endpoint is the change in motor severity as measured by the Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) at three months post-treatment. Secondary endpoints include adverse event frequency, patient and clinician global impressions of change, disability assessments (e.g., QuickDASH), quality of life (SF-36), and neurocognitive testing.
Additionally, the study will incorporate neurophysiological (TMS) and neuroimaging (resting-state fMRI) techniques to investigate treatment-induced changes in cortical excitability, plasticity, and functional connectivity, providing insight into the neural mechanisms underlying clinical improvement.
The FUTURE study is coordinated by the Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy with participation from other three major Italian neurological institutes. It represents a pioneering effort to evaluate focused ultrasound as a non-invasive therapeutic option for patients with disabling and treatment-resistant forms of limb dystonia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients undergo unilateral pallidotomy using Exablate system under MRI guidance.
Device: Exablate MR-guided Focused Ultrasound Pallidotomy
Identical setup without thermal lesioning. Participants cross over to active Pallidotomy after 3 months.
Device: Exablate MR-guided Focused Ultrasound Pallidotomy · Device: Sham Sham Exablate MRgFUS Pallidotomy
Active Pallidotomy
Sham procedure. Identical setup without thermal lesioning. Participants cross over to Active Pallidotomy after 3 months.
Chenge in the Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS)
The BFMDRS has a maximum score of 120 for the movement subscale and 30 for the disability subscale. Higher scores indicating more severe dystonia.
Time frame: Baseline to Week 12
Incidence of treatment-related adverse events
Assessment of any treatment-related adverse events throughout the whole study period
Time frame: Baseline to Week 24
Changes in the Quick Disabilities of Arm, Shoulder & Hand (Quick-DASH) score
The QuickDASH is a shortened, 11-item version of the DASH Outcome Measure, designed to assess physical function and symptom severity related to the arm, shoulder, and hand. Maximum score 100; the greater the score the grear the disability.
Time frame: Baseline, Week 12 and Week 24
Changes in the Clinical Global Impression of Change (CGIC) score
The CGIC is a 7-point scale used to assess the degree of change in a patient's condition since the start of treatment or another defined baseline. Lower scores indicates improvement and higher scores indicating worsening of the patient's condition.
Time frame: Baseline, week 12 and week 24
Patient Global Impression of Change (PGIC)
The maximum score of the PGIC is 7: the higher the score the higher the improvement reported by a patient.
Time frame: Baseline, Week 12 and week 24
Change in the 36-Item Short Form Survey (SF-36) score
The SF-36 questionnaire has a maximum score of 100 for each of its eight scaled scores (physical functioning, role limitations due to physical health, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health). The higher the scores the more favorable is health state within that specific dimension.
Time frame: Baseline, week 12 and week 24
Changes in the Short-Interval Cortical Inhibition (SICI)
This is a neurophysiological measure of inhibitory processes within the motor cortex, assessed using Transcranial Magnetic Stimulation, which is measured as the relative amplitude reduction of motor evoked potentials from the test stimulus when it is preceded by the conditioning stimulus. The greater the change in SICI, the greater the pallidotomy-induced changes in motor cortex intracortical inhibitory circuits
Time frame: Baseline and Week 24
Changes in intracortical facilitation (ICF)
This is a neurophysiological measures of cortical excitability, assessed using paired-pulse Transcranial Magnetic Stimulation, which describes an increase in the magnitude of a motor evoked potential in a target muscle when a suprathreshold test pulse is preceded by a subthreshold conditioning pulse at specific interstimulus intervals. The greater the change in ICF, the greater the pallidotomy-induced changes in intracortical excitatory circuits
Time frame: Baseline and Week 24
Changes in Paired Associative Stimulation (PAS)
This is a neurophysiological measure of cortical plasticity assessed using transcranial magnetic stimulation. The greater the change in PAS, the greater the pallidotomy-induced changes in motor cortex synaptic plasticity
Time frame: Baseline and week 24
Changes in brain activity (using functional connectivity) using resting-state functional magnetic resonance imaging (rs-fMRI)
The investigators will conduct a region-of-interest analysis to calculate changes of fMRI functional connectivity between baseline and post-pallidotomy.
Time frame: Baseline and Week 24
Changes in pallidotomy lesion morphology via contrast MRI
To evaluate the morphological changes of the lesion after 24 hours, 3 months and 6 months from pallidotomy using contrast-enhanced brain MRI and their relationship with clinical changes including adverse events.
Time frame: 24-hour after the procedure, week 12 and week 24
Changes in the Montreal Cognitive Assessment (MoCA) score
Changes in the Montreal Cognitive Assessment (MoCA) score, a 30-point test of global cognitive functions. Score range: 0-30, with lower scores indicating worse cognitive function and higher scores indicating better cognitive function.
Time frame: Baseline, week 12 and week 24
Change in Digit Span test score
Change in Digit Span test score, a cognitive test assessing memory functions. Score range: 0-\[insert maximum score for the test\], with lower scores indicating greater memory impairment and higher scores indicating better memory function.
Time frame: Baseline, week 12 and week 24]
Change in the Stroop Test score
Change in Stroop Test scores, a neuropsychological test assessing frontal-lobe executive cognitive function. Score range: \[insert minimum\]-\[insert maximum\], with higher scores or slower reaction times indicating worse executive cognitive function.
Time frame: Baseline, week 12 and week 24
Plan to share: Yes — Data will be shared upon reasonable request with appropriate safeguards for privacy and confidentiality
Time frame: Data requests can be submitted starting 9 months after article publication and the data will be made accessible for up to 24 months. Extensions will be considered on a case-by-case basis
Access criteria: Access to trial individual participant data can be requested by qualified researchers engaging in independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan and execution of a Data Sharing Agreement. For more information or to submit a request, please contact the P.I. of the study
Started Jan 2025 (actual). Primary completion is estimated for Feb 2027, 25 months after the start.
Of 48 non-industry interventional studies with no phase under Dystonia, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 75. This study's planned 25 months is below that.
Counting every sponsor, half of 49 studies reached it within 50 months; a quarter within 26 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta